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ABSTRACT   
Background: The acute coronary syndrome is a consequence of coronary artery disease. Creatine Kinase MB is a cardiac 
biochemical marker used in the diagnosis and risk stratification of patients. The diabetes is a pathology associated to acute 
coronary syndrome non–ST segment elevation that change the cardiac conditions, in this sense, our objective was to evaluate the 
modifications of cardiac biomarkers values in diabetic patients. Materials and methods: A retrospective study included 155 
patients of both sexes, ages ranging from 31 to 92 years old, admitted to the coronary unit of the “Reina Fabiola” Clinic, Córdoba, 
Argentina was performed in the period 2014-2015. Body mass index, time consultation pain, plasmatic Creatine Kinase 
isoenzyme MB activity and Troponin I levels were measured. The patients were stratified into two groups: without cardiovascular 
risk pathologies (Control group), n = 7; and with only type II diabetes, n = 64 treated with therapeutic doses of metformin (n= 37), 
and glibenclamide plus glizipide (n= 27). Results: cTnI levels were lower in both pharmacological treatments at 12 hrs when the 
values in control reach the highest. Similarly, CK-MB activity was lower at 8 hrs in both treatments; however at 12 hrs these 
values were lower only with metformin but not in glibenclamide plus glizipide treatment. These results could be showing an 
interaction between diabetes and pharmacological treatment upon the biomarkers values. Conclusion: The use of hypoglycemic 
drugs and the glycometabolic state are conditions that could modify CK-MB and cTnI release/clearance balance at 8 and 12 hrs 
after admission to the coronary unit. 
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INTRODUCTION
The acute coronary syndrome (ACS) is a consequence of 
coronary artery disease, characterized by myocardial 
ischemia and reduction of the artery diameter with 
inflammation of endothelial wall cell. The ACS can be 
caused by unstable angina with non–ST segment elevation 
(NSTEMI) or myocardial infarction with ST-segment 
elevation (STEMI) [1]. Cardiac molecular markers are used 
in the diagnosis and risk stratification of patients with chest 
pain and suspected ACS. Creatine Kinase-MB (CK-MB) 
values are important to define unstable angina or NSTEMI, 
even in the absence of electrocardiogram (ECG) changes [2, 
3]. Actually CK-MB and troponin I (cTnI) are used as 
markers of myocardial injury cardiospecific for correct 
diagnosis [4]. cTnI is one of predictive markers more 
sensitive used in the stratification of necrosis myocardial 
and the subsequent therapeutic efficacy [5]. In pathologies 
such as decompensated diabetes several cardiac markers 
including cTnI are elevated in patients without ACS [6]. 
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There are factors that influence the risk of coronary artery 
disease such as age, sex, family history and ethnicity. But 
there are risk factors that can be modified, including 
elevated levels of serum cholesterol, LDL cholesterol, 
triglycerides, lower levels of HDL cholesterol, diabetes type 
II, smoking, obesity, sedentary lifestyle, hypertension and 
stress [7].  
Diabetes is a risk factor for cardiovascular disease and 
according to epidemiological data death in the diabetic 
population caused by cardiovascular disease reached 65%. 
This disease has one of the highest morbidity and mortality 
levels and the prevalence of NSTEMI increases to double 
[8], although the incidence of ACS can be decreased with 
preventive treatments [9].  
Studies associating factors like angiogenic changes, 
oxidative stress and diabetes are important when evaluating 
cardiac tissue response to ischemic injury. In diabetic 
patients with unstable angina, the expression of hypoxia-
inducible factor-1α (HIF) and vascular endothelial growth 
factor (VEGF) are reduced in parallel with lower levels of 
nitric oxide synthase (NOS) activity. All these together, lead 
to an increased oxidative stress worsening the angiogenesis 
process [10]. Diabetic patients have less collateral vessels 
and this condition causes a more severe injury during 
coronary ischemia [11].  
There are many contradictions regarding the response of the 
diabetic heart to ischemia. In this sense, there are data 
suggesting an increased vulnerability of the diabetic 
myocardium to the ischemic injury [12]. The diabetes as 
pathology associated to NSTEMI could change the 
physiological cardiac conditions; in this sense our objective 
was to evaluate the effect of pharmacological treatment on 
cardiac biomarkers in patients with acute coronary 
syndrome of non–ST segment elevation with Type-2 
diabetes. 
 
MATERIALS AND METHODS 
A retrospective study included 155 patients of both sexes, 
ages ranging from 31 to 92 years old, and admitted to the 
coronary unit of the “Reina Fabiola” Clinic, Córdoba, 
Argentina with an ACS diagnosis in the period 2014-2015. 
The patients were separated into two groups: without 
cardiovascular risk pathologies (Control group), n = 7; and 
only with type II diabetes, n = 64 treated with therapeutic 
doses of metformin (n= 37), and glibenclamide plus 
glizipide (n= 27). Seventy-four patients with other 
associated pathologies and five diabetic patients treated with 
another drugs were excluded from the study. 
An uncorrected weight was estimated using the body mass 
index (BMI) measured by height (in meters) and weigh (Kg) 
relation (weigh/height2). Time consultation pain (TCP) was 
taken into account: the time (in hours) elapsed from the 
onset of chest pain until the inquiry to the coronary unit. 
Plasmatic CK-MB activity was measured by the kinetic 
method Biosystem ®. Plasmatic cTnI levels were measured 
by Enzyme Linked Fluorescent Assay (ELFA) Biomeriux 
(France). The amount of enzyme required to transform a 
µmol of substrate per minute was considered as an 
international unit (IU). The normal reference values of the 
CK-MB were considered less than 25 IU [13]. The normal 
reference value of cTnI was considered ≤ 0.01 ng/ml. To 
study the kinetics of markers, the values were obtained at 
admission to the coronary unit (0 hs), after 8, 12 and 24 
hours for CK-MB and 0, 8, 12, 24 and 36 for cTnI; 
thereafter the patients were submitted to coronary 
angiography.  
Multiple correlation analysis and ANOVA II followed by 
the Sidak's post hoc test, and Chi square were performed. 
The values of p < 0.05 were considered significant. 
Limitations of this study 
Our court of patients as control group has low number of 
them because they have acute coronary syndrome without 
cardiovascular risk pathologies. This condition is 
uncommon, but allows to discard the effects of other 
frequent pathologies in patients with NSTEMI.   
Ethical statement 
The current study protocol was approved by the Bioethical 
Committee of the “Reina Fabiola” Clinic and the Catholic 
University of Córdoba. All participants were enrolled upon 
signing written informed consent. All governmental and 
institutional regulations regarding the ethical involvement of 
human volunteers in clinical studies were respected. 
RESULTS  
Positive correlation was found between CK-MB activity in 
the plasma and TPC at 12 hours (Table 1). No differences 
were found between sexes and biomarkers in all studied 
times (Figure 1 A, B). 
 
Table 1: Pearson correlation between CK- MB, cTnI and age, BMI, TPC at the time of admission to the coronary care unit 
(0 hours), 8, 12, 24 and 36 hours 
Hours  0  8 12 24 36 
CK-MB(UI/L) Age 0.09 -0,12 -0,027 0,03  
 BMI 0,03 -0,07 -0.08 -0,16  
 TPC 0,03 -0,003 0,25 † 0,20  
cTnI (µg/ml) Age -0.01 -0,03 -0,07 -0,008 -0.14 
 BMI 0.03 -0.06 -0.16 0.20 -0.05 
 TPC 0.06 -0.14 0.03 0.01 0.12 
BMI (body mass index), TPC (time consultation pain). †p <0.05  
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Figure 1: Values of the plasma CK-MB (Panel A) and cTnI levels (panel B) of both sexes studied at 
the time of admission to the coronary care unit (0 hours), and after 8, 12, 24 and 36 hours. The 




Table 2: Percent of patients who have high or low values CK- MB and cTnI respect to the references 
values in control and diabetes groups at the time of admission to the coronary care unit (0 hours), 8, 
12, 24 and 36 hours. 
 Time (hours) 0  8 12  24 36 
 CK-MB      
Control ≤ 25UI/L 71.4 42.8 57.1 33.3 - 
> 25UI/L 28.5 57.1 42.8 66.6 - 
Diabetes ≤ 25UI/L 69.5 80.9 84.4 75.7 - 
> 25UI/L 28.9 19.0 15.5 24.2 - 
  P= 0.6 P<0.05 P=0.1 P=0.1  
 cTnI      
Control ≤0,01ng/ml 14.2 14.2 14.2 50.0 33.3 
>0,01ng/ml 85.7 85.7 85.7 50.0 66.6 
Diabetes 
 
≤0,01ng/ml 53.6 55.2 60.3 50.0 73.3 
>0,01ng/ml 44.7 46.3 39.6 50.0 26.6 
  P=0.5 P=0.06 P<0.05 P=0.6 P=0.07 
P < 0.05 diabetes vs control group 
 
The percentage of patients that have high /low ratio values 
of CK-MB (>25UI/L)/(≤ 25UI/L) and cTnI (>0.01ng/ml)/( ≤ 
0.01 ng/ml) are lower in diabetic group at 8 hs; (chi2 = 5. 19) 
p < 0.05 and 12 hs (chi2 = 5. 36) p < 0.05 respectively; 
(Table 2). When diabetics patients were separated in 
metformin and glibenclamide plus glizipide treatment, the 
analysis of CK-MB activity two-way ANOVA showed 
significant differences in treatment condition, F (2, 218) = 
8.08; P< 0.05.  
 
Multiple comparisons Sidak’s post hoc test indicated that 
there were significant low levels of metformin treated 
diabetic patients respect to the control group 52.7 ± 28.4 vs 
185.9 ± 85.7, t= 3.45, P < 0.05, glibenclamide plus glizipide 
24.5 ± 5.5 vs 185.9 ± 85.7, t= 4.12, p < 0.05 at 8 hs and 
metformin 17.9 ± 2.5 vs 121.0 ± 74.3, t= 2.48 at 12 hs after 
admission to the coronary care unit (Figure 2 A). 
 
cTnI levels showed significant differences in treatment 
condition F (2, 259) = 4.59 P < 0.05. Multiple comparison 
Sidak’s post hoc test indicated that there was a decreased in 
the cTnI levels in metformin treatment respect to the control 
group at 12 hs 0.36 ± 0.20 vs 2.00 ± 0.93, t = 3.85, P < 0.05, 
glibenclamide + glizipide 0.68 ± 0.27 vs. 2.00 ± 0.93, t = 
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Figure 2. Values of the plasma CK-MB activity (Panel A) and cTnI levels (Panel B) in control group and patients treated 
with metformin or glibenclamide plus glizipide at the time of admission to the coronary care unit (0 hours), and after 8, 12, 
24 and 36 hours. The values represent the mean ± SEM. * p< 0.05 Control vs. treatment group. 
 
DISCUSSION 
Biochemical cardiac markers as CK-MB and cTnI are used 
in the diagnosis and risk stratification of patients with chest 
pain and suspected ACS [13]. Studies of diseases as heart 
failure and others highlight the positive correlation between 
either age, sex and cTnI levels [14]. Although the range of 
age (31-92 years) of studied patients was large, we did not 
found correlation between these parameters in diabetic 
patients. In this way, no differences were found in CK-MB 
activity and cTnI levels in both sex. 
Keller, et al showed that increased troponin levels are 
related to the early diagnosis of ACS according to the time 
of consultation after the onset of chest pain [15]. In patients 
with NSTEMI the evaluation during the admission to care 
unit is important and the reperfusion therapy should not be 
delayed pending to the biomarkers, they are used only if the 
symptoms persist after 6-8 hours. For this reason, is not 
recommendable to use biomarkers in the diagnostic at the 
moment of pain consultation [16]. In this way, cTnI 
specifically has the most sensibility in the early 
cardiovascular risk stratification to diagnosis and prognosis 
at the same time. It is recommended to increase the cTnI 
sensitivity in the diagnosis of myocardial injury to take 
samples in emergency room and 6 to 9 hours later, since it is 
not reliable within 2 to 4 hours taking into account the delay 
in time of pain consultation [17].  
TPC range in patients in our study was from 1 to 8 hours 
and results showed that there were no correlations between 
CK-MB, cTnI and TPC and in this way the delay in the 
biomarkers measure is not relevant in the damage prognosis 
although there was a positive correlation in TPC with CK-
MB at 12 hours of coronary unit admission.  
It is known that CK-MB and cTnI have different sensibility 
in the ACS diagnosis confirmation but their levels can be 
modified by comorbidities and muscle injuries.  
 
 
The percentage of patients with CK-MB values above 25 
IU/L is similar in the control (28.5%) and diabetic group 
(28.9%) at 0 hours, but there was an increase in the number 
of patients with high levels of CK-MB in control group 
(66.6%) and lower (24.8%) of diabetic patients within 24 
hours. Analyzing the corresponding cTnI results the 
percentage of patients with values greater that 0.01 ng/ml 
was higher (85.7%) in controls, but it is important to remake 
the decrease to 39.6% of diabetic patients at 12 hours, 
indicating that type II diabetes will be implicated in the loss 
of biomarkers sensibility. 
CK-MB is diagnostic specific for myocardial injury, but it 
depends on the muscle mass and it has also been reported 
that it increases with exercise or in patients with respiratory 
difficulties, whose chest muscles have more activity. This 
feature affects the specificity, particularly in patients with 
concomitant myocardial and skeletal muscle injury [18].  
cTnI is important to evaluate the muscle ischemia because is 
the most specific and sensitive laboratory marker of 
myocardial cell injury. [19].  
Diabetic patients in our study were treated with metformin 
or glibenclamide plus glizipide. cTnI levels were lower in 
both treatments at 12 hs when the control values reach the 
highest. Similarly, CK-MB activity was lower at 8 hs in 
both treatments; however at 12 hs this value was lower only 
with metformin but not in glibenclamide plus glizipide 
treatment. These results could be showing an interaction 
between diabetes and pharmacological treatment on the 
biomarkers values.  
The use of effective normoglycemic drugs as metformin 
acquires importance in diabetic patients with risk of 
coronary events. In these cases, it has been shown that the 
use of metformin reduces the CK-MB activity and cTnI 
levels compared to untreated metformin diabetic patients 
[18, 20]. Besides, benefits in chronic coronary disease have 
been observed [21]. The cardio protective effect of 
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metformin in the preconditioned ischemia was associated to 
the activation of kinases, which increases the intracellular 
adenosine.  
One of the end effectors of preconditioned ischemia that 
protects cells such as cardiomyocytes against ischemic cell 
death seems to be the mitochondrial hexokinase II, that is 
increased by metformin [22]. When the episode of angina 
pectoris precedes the appearance of the acute myocardial 
infarct, it is found to be associated with a smaller size of the 
infarction, improvement of left ventricular function and 
survival. However, the possibility that patients with diabetes 
type II were protected by ischemic preconditioning is still 
discussed. There are divergences regarding the cardio 
protective effects of ischemic preconditioning where some 
authors suggest that this effect is lost and others that the 
diabetic hearts are more protected[23].  
In preclinical studies using diabetic rats induced by 
streptozotocin, the infarct size was similar to those of non-
diabetic rats after 45 minutes of ischemia, and the release of 
CK-MB in plasma was higher in diabetic rats. Other studies 
showed that the infarct size, ischemia intensity and CK-MB 
levels do not reach their maximum values at the same time. 
Other deleterious effects of diabetes have also been 
described such as left valvular ejection fraction decrease, 
after 30 minutes of ischemia, which was reduced in diabetic 
rats respect to non-diabetic control group [24]. 
Prospective clinical trials analyzed the release of cardiac 
enzymes, as preconditioning by angina pandromal, as an 
assessment of the size of the infarction, but did not found 
beneficial effects. Thus, there is insufficient evidence that 
allows to conclude that the mechanism has a relevant role in 
diabetic patient. Therefore, more clinical trials will be 
necessary to observe the relationship between myocardial 
preconditioning and diabetes.  
There are discussions about the previous ischemic 
preconditioning with lower percutaneous coronary 
intervention related to cTnI release respect to major adverse 
cardiac events. Diabetic patients require a higher threshold 
of preconditioning due to metabolic and ATP sensitive 
potassium channels alterations. The reduction in cTnI was 
also observed in cycles of the ischemic conditioning 
stimulus [25]. Others authors suggest that the evolution of 
ischemic damage and the possible release of cardiac 
enzymes show similar values in diabetic and non-diabetic 
patients [26]. 
It is important to stand out that in our diabetic patients 
treated with hypo and normoglycemic drugs, there was a 
decreased CK-MB activity (8hs) and cTnI levels (12hs) 
respect to control group. This possibly could be a 
consequence of the interaction between the use of 
hypoglycemic drugs and the glycometabolic state that could 
modify the CK-MB and cTnI release/clearance balance at 8 
and 12 hs after admission to the coronary unit. 
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